Absci is trading 5.06% up now at $8.72, primarily amid biotech-sector momentum.
- No new company-specific announcement was identified for August 7, 2026.
- Biotech ETF XBI is up 2.09% during regular trading, supported by Argenx’s announced tender offer for Forte Biosciences and broader merger-and-acquisition optimism.
- Absci’s second-quarter results are due August 11 and may be supporting interest, but evidence does not establish them as today’s direct catalyst.